Search
126 matches for “primary progressive”
Trials (35)
- ND: An open-label, prospective, multicentric pilot study evaluating safety and symptomatics effects of low dose Naltrexone in patients with primary progressive multiple sclerosis.
- A pilot single-centre randomised controlled trial of recombinant human erythropoietin versus placebo in primary progressive multiple sclerosis.
- efficacy and safety of 0.5 mg fingolimod in patients with primary progressive multiple sclerosis: A study to evaluate how safe and effective 0.5 mg FTY720 is in delaying disability progression if taken once daily, in patients with PPMS
- FUMAPMS: Treatment with dimethyl fumarate in patients with primary progressive multiple sclerosis
- A phase 3 study to compare efficacy and safety of masitinib with placebo in the patients with primary progressive or secondary progressive multiple sclerosis without relapse.
Hypotheses (56)
- B-cell depletion (anti-CD20): protect nerve tissue in primary progressive MS
- Broad immunosuppression / cytotoxics: protect nerve tissue in primary progressive MS
- Tacrolimus anhydrous: protect nerve tissue in primary progressive MS
- Cell therapies and tolerisation: protect nerve tissue in primary progressive MS
- DHODH inhibition (pyrimidine synthesis): protect nerve tissue in primary progressive MS
Papers (34)
- Risk factors associated with the onset of relapsing-remitting and primary progressive multiple sclerosis: a systematic review. ↗
- Evaluation of Study and Patient Characteristics of Clinical Studies in Primary Progressive Multiple Sclerosis: A Systematic Review. ↗
- A systematic review about the epidemiology of primary progressive multiple sclerosis in Latin America and the Caribbean. ↗
- Consensus recommendations for the diagnosis and treatment of primary progressive multiple sclerosis in Latin America. ↗
- Gray Matter Atrophy in the Cortico-Striatal-Thalamic Network and Sensorimotor Network in Relapsing-Remitting and Primary Progressive Multiple Sclerosis. ↗
Lab studies (1)
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error